Profile: Biocept Inc (BIOC.A)
15 Aug 2019
Biocept, Inc., incorporated on June 28, 2013, is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's breast, lung and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on characteristics of their patients' tumors.
The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma. These assays utilize its dual CTC and ctDNA technology platform and provide biomarker analysis from a standard blood sample. In the case of its breast and gastric cancer offering, biomarker analysis involves fluorescence in situ hybridization (FISH), for the detection and quantitation of the human epidermal growth factor receptor 2 (HER2), gene copy number, as well as immunocytochemical analysis of estrogen receptor (ER) protein.
The Company's lung cancer biomarker analysis includes FISH testing for anaplastic lymphoma receptor tyrosine kinase (ALK) and Proto-oncogene tyrosine-protein kinase 1 (ROS1) gene rearrangements and mutation analysis of the T790M, Deletion 19 and L858R mutations of the epidermal growth factor receptor (EGFR) gene, as well as B-RAF and K-RAS using its Target-Selector platform. For lung cancer, it also offers a resistance panel assay consisting of the biomarkers MET, HER2 and T790M, which is performed using ctDNA in plasma. Fibroblast growth receptor 1 (FGFR1), amplification is offered using its CTC technology. FGFR1 is present in several tumor types, including both NSCLC and SCLC.
The Company's Target-Selector melanoma assay is performed on a standard blood sample, and provides information on the presence or absence and specific nature of the V600 mutation in the B-RAF gene, which indicates whether the B-RAF inhibitors are candidate therapies for the patient. Its Target-Selector assay for colorectal cancer offers mutation testing analogous to that performed in lung cancer, namely detection of key mutations in the K-RAS and B-RAF genes. Its Target-Selector assay for prostate cancer is based on the analysis of CTCs found in a standard blood sample. The Company also offers laboratory testing services and clinical trial services.
The Company competes with Atossa, Qiagen, Roche, Trovagene, Guardant, Janssen Diagnostics, Alere, Illumina, Apocell, EPIC Sciences, Clearbridge Biomedics, Biodesix, Thermo-Fisher, Dako A/S, Foundation Medicine, Neogenomics, Cynvenio Biosystems, Genomic Health, Fluxion Biosciences, RareCells, ScreenCell, Silicon Biosystems, Sonic USA, Quest, LabCorp, Caris, Agendia, Genoptix, Pfizer Inc., Abbott Laboratories, Inc., Daiichi Sankyo, Inc., GlaxoSmithKline and bioMerieux.
5810 Nancy Ridge Dr
SAN DIEGO CA 92121-2834